Phase 2b study evaluating diagnostic performance of 18F-RAD101 for suspected recurrent brain metastases from solid tumors of different origins Underscores Radiopharm’s commitment to developing transformative oncology radiopharmaceuticals Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, ‘Radiopharm’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high…
As data breaches and cyberattacks rise, cybersecurity exchange-traded funds (ETFs) are gaining traction. The term cybersecurity originated in 1989,…
Sarama Resources (SRR:AU) has announced Initial Exploration Program Completed at Cosmo Gold Project Download the PDF here. This post…
John Ciampaglia, CEO of Sprott Asset Management, shares his outlook for the gold price. ‘To us, gold could continue…
Continuing his administration’s push toward reducing US reliance on Chinese mineral imports, President Donald Trump has signed a new…
‘Never miss out on an opportunity like a recession’ — Jack Welch, former chairman and CEO of General Electric.…
Radiopharm Theranostics (RAD:AU) has announced First patient dosed in Phase IIb imaging for Brain Mets Download the PDF here.…
Brightstar Resources (BTR:AU) has announced RHI: Acqn of royalty over Sandstone Gold Project tenements Download the PDF here. This…